首页> 外文会议>Conference on vaccine technology VI >HIGHLY EFFICIENT INFLUENZA VIRUS PRODUCTION: A MDCK-BASED HIGH-CELL-DENSITY PROCESS
【24h】

HIGHLY EFFICIENT INFLUENZA VIRUS PRODUCTION: A MDCK-BASED HIGH-CELL-DENSITY PROCESS

机译:高效的流感病毒生产:基于MDCK的高细胞密度过程

获取原文

摘要

Seasonal vaccination campaigns for influenza in developed and developing countries create a massive demand for 500 million (2015) vaccine doses every year [1]. Besides egg-based vaccine manufacturing, production platforms based on animal cell culture increasingly contribute to this overall growing market. In order to intensify cell culture-based influenza virus production, high-cell-density (HCD) cultivation of suspension cells can be applied to improve virus titer, process productivity and production costs [2], For process optimization and evaluation of HCD conditions, cells cultivated using semi-perfusion approaches in small shakers can be used as a scale-down model for bioreactors operating in full perfusion mode [3]. In this study, a previously developed MDCK suspension cell line [4] was adapted to a new serum free medium [5] to facilitate higher growth rate, cell density and virus titer both in batch and in HCD. Therefore, MDCK cells cultivated in Smif-8 medium were slowly adapted to a new cultivation medium (Xeno™) by stepwise increasing the Xeno content. Fully adapted cells were cultivated in shaker flasks to evaluate the performance of influenza A virus production in batch and HCD. Cell densities exceeding 2·10~7 cells/mL were achieved in shakers using semi-perfusion, where cell free medium was manually replaced with fresh medium. Volume and time interval of media replacement were chosen to achieve a constant cell-specific perfusion rate of 2.5 pL/(cell h). Cell cultures were infected with influenza virus (A/PR/8/34 H1N1 RKI) with trypsin addition. Cell count, viability, main metabolites and virus titer (HA-assay & TCID_(50)) were monitored pre and post infection. Medium adaptation resulted in a MDCK suspension cell line with morphological, growth, and metabolic characteristics different from parental cells. Cells fully adapted to Xeno medium were growing to higher cell densities (1.4·10~7 vs 6·10~6 cells/mL) with higher specific growth rate (μ_(max): 0.036 vs 0.026 1/h), cells were bigger (15-16 vs 13-14 μm) and grew without aggregate formation. Due to higher cell densities at time of infection, virus titers up to 3.6 log_(10)(HAU/100μL) were reached. In semi-perfusion, adapted MDCK cells were grown up to 6·10~7 cells/mL, however, maximum virus titer and productivity were observed with 4·10~7 cells/mL. In multiple harvests, very high virus titer exceeding 4 log_(10)(HAU/100μL) and up to 9·10~9 virions/mL (TCID_(50)) were measured, which corresponded to an accumulated titer of 4.5 log_(10)(HAU/100μL). Cell-specific virus titer was similar or higher compared to the reference batch infections, depending on perfusion and infection strategy. Overall, results in this semi-perfusion scale-down model for influenza A virus production suggest a highly efficient and productive upstream process for influenza virus production, with an up to six-fold improved space time yield compared to batch mode.
机译:发达国家和发展中国家的季节性流感疫苗接种运动每年产生大量需求,即每年需要5亿(2015)剂疫苗[1]。除了基于鸡蛋的疫苗生产外,基于动物细胞培养的生产平台也日益为这一整体增长的市场做出贡献。为了加强基于细胞培养的流感病毒的生产,悬浮细胞的高细胞密度(HCD)培养可用于提高病毒滴度,工艺生产率和生产成本[2],用于工艺优化和HCD条件评估,在小型振荡器中使用半灌注方法培养的细胞可以用作以全灌注模式运行的生物反应器的按比例缩小模型[3]。在这项研究中,先前开发的MDCK悬浮细胞系[4]适用于新的无血清培养基[5],以促进批次和HCD中更高的生长速率,细胞密度和病毒滴度。因此,通过逐步增加Xeno含量,使在Smif-8培养基中培养的MDCK细胞缓慢适应新的培养基(Xeno™)。在摇瓶中培养完全适应的细胞,以分批和HCD评估甲型流感病毒生产的性能。使用半灌注在摇床中获得超过2·10〜7个细胞/ mL的细胞密度,其中无细胞培养基手动替换为新鲜培养基。选择培养基置换的体积和时间间隔以实现恒定的细胞特异性灌注速率2.5 pL /(cell h)。细胞培养物被添加了胰蛋白酶的流感病毒(A / PR / 8/34 H1N1 RKI)感染。感染前后监测细胞计数,活力,主要代谢产物和病毒滴度(HA测定和TCID_(50))。培养基适应导致MDCK悬浮细胞系的形态,生长和代谢特征不同于亲代细胞。完全适应Xeno培养基的细胞生长到更高的细胞密度(1.4·10〜7 vs 6·10〜6细胞/ mL),比生长速率更高(μ_(max):0.036 vs 0.026 1 / h),细胞更大(15-16 vs 13-14μm),并且没有聚集体形成。由于感染时细胞密度较高,因此病毒滴度高达3.6 log_(10)(HAU /100μL)。在半灌注中,适应的MDCK细胞生长至6·10〜7细胞/ mL,但是,在4·10〜7细胞/ mL时观察到最大的病毒滴度和生产率。在多次收获中,测得的病毒滴度非常高,超过4 log_(10)(HAU /100μL),高达9·10〜9病毒粒子/ mL(TCID_(50)),相当于累积滴度为4.5 log_(10) (HAU /100μL)。细胞特异性病毒滴度与参考批次感染相似或更高,具体取决于灌注和感染策略。总体而言,这种针对甲型流感病毒生产的半灌注缩小模型的结果表明,一种高效高效的上游生产流感病毒的过程,与分批模式相比,时空产量提高了六倍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号